When exogenous testosterone therapy is. adverse responses can be induced.

Size: px
Start display at page:

Download "When exogenous testosterone therapy is. adverse responses can be induced."

Transcription

1

2 Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release of testosterone and possible stimulation of remaining androgen sensitive elements. When exogenous testosterone therapy is administeredto to patients with symptomatic CRPC, adverse responses can be induced.

3

4 Taylor (JCO 1993) retrospective (341 pts) continued testicular androgen suppression was an important tpredictor of survival lduration (modest advantage) Hussain (JCO 1994) retrospective (205 pts) no obvious bi advantages in response to chemotherapy or survival for pts with continued gonadal suppression Lee (Am J Clin Oncol 2011) prospective (78 pts) brr (48.7% vs 66.7% p=0.27) PFS (4.9 mosvs5.0 mos p=0.57)

5 ADT is advocated to be used continuously, when chemotherapy is proposed p for CRPC

6 No robust evidences support the ADT maintenance during chemo Theoretical advantages could be postulated If well tolerated, ADT may be continued

7

8 1990 s scenario HT XRT PIB HT HT CHT RP HT CHT hormone res metastases

9 Mitoxantrone Tannock JCO 1996; 14:1756 MIT+PDN PDN Kantoff JCO 1999; 17: 2506 MIT+HC HC Better palliation with MIT Increased DFS with MIT No differences in survival

10 SWOG and TAX studies in HRPC

11 TAX327 original results Pr robability of Surviving D 3 wkly 0.8 D wkly 0.7 Mitoxantrone Median Hazard Survival Ratio P value Combined: D 3 wkly: D wkly: Mitoxantrone: Months Tannock et al, N Engl J Med 2004; 351: months

12 TAX327 confirmatory data of survivi ing Pro obability Docetaxel q3w Docetaxel qw Mitoxantrone Median survival Hazard (months) ratio p value Docetaxel q3w: Docetaxel qw: Mitoxantrone Years months 48 months Berthold DR, et al. J Clin Oncol 2008;26:

13 1990 s scenario HT XRT PIB HT HT CHT RP HT CHT hormone res metastases

14 2004 scenario HT XRT PIB HT HT CHT RP HT CHT hormone res metastases

15

16 M0 Maintain castration levels of testosterone Clinical trial Observation Further hormonal manipulation ASYMPTOMATIC M1 Maintain castration levels of testosterone SYMPTOMATIC only bone mets DOC Zoledronic acid SYMPTOMATIC visceral mets DOC

17 TAX327:Multivariate Cox proportional p hazards Variable Multivariate 95% CI p value HR Liver metastases Number of metastatic sites (>2 vs 2) Pain at baseline < Performance status ( 70 vs 80) Progression type Measurable disease Bone scan Baseline PSA doubling time (<55 days vs 55 days) Baseline log PSA (for every unit rise in log(psa) in ng/dl) <0.001 Tumour grade (Gleason 8 or WHO 3 4 vs Gleason 7 or WHO 2 3) Alkaline phosphatase (log scale) (per log unit rise, IU/L Haemoglobin) Haemoglobin (per unit rise, g/dl) Armstrong et al Clin Canc Res 2007;13:

18 Prognostic Nomogram in CRPC Chemotherapy type Liver metastases Number of sites Pain at baseline Points Weekly Doce (6) Q3 Doce Mitox (18) No Yes (23) <=2 >2 (22) No Yes (18) Karnofsky performance status >=80 <70 (15) Progression type: Measurable disease No Yes (15) Progression type: Bone scan progression No Yes (12) Tumour grade Baseline PSA (ng/ml) Alkaline phosphatase (IU/L) Haemoglobin (g/dl) Baseline PSA doubling time Total points Median survival time (mo) Low Grade 0 18 High Grade (8) (5) 1 2 (13) 14 >6 2 3 (12) <1 (19) yr survival probability yr survival probability 5 yr survival probability Armstrong et al Clin Canc Res 2007;13:

19 Simplified Model Risk factors Anemia (hemoglobin <13.0) laboratory data Progression by bone scan criteria clin. data Visceral metastases clin. data Presence of clinically significant pain (TAX 327 definition) clin. data Armstrong et al Clin Canc Res 2007;13:

20 Simplified Model

21 Simplified Model Low Risk: 0-1 risk factors Intermediate Risk: 2 risk factors High Risk: 3-4 risk factors

22

23 TAX 327 Survival: pain vs no pain/minimal Docetaxel q3w Docetaxel qw Mitoxantrone (n = 335) (n = 334) (n = 337) N O P A I N P A I N n Median survival Hazard ratio p value n Median survival Hazard ratio p value Berthold DR, et al. J Clin Oncol 2008;26:242 45

24 TAX 327 Survival: pain vs no pain/minimal Docetaxel q3w Docetaxel qw Mitoxantrone (n = 335) (n = 334) (n = 337) N O P A I N P A I N n Median survival Hazard ratio p value n Median survival Hazard ratio p value Berthold DR, et al. J Clin Oncol 2008;26:242 45

25 Pre Treatment PSA DT PSADT >6 months PSADT 4 6 months PSADT 2 3 months PSADT 1 2 months PSADT <1 month Surviva al (%) and 3-6 Med OS NYR mean OS 25 and 22.5 months < 1 mo months 0 Log-rank p< Survival (months) Armstrong et al Clin Canc Res 2007;13:

26 Overall Survival according to bone pain intensity i and PSA doubling time (DT) No or minimal pain Mild pain Moderate or severe (n=79) (n=41) pain (n=25) Median OS 21.4 mos ( ) 15 mos ( ) 13.1 mos ( ) PSA DT > 45 days 32.4 mos 18.4 mos 16.1 mos PSA DT < 45 days 16.5 mos 11.2 mos 8.3 mos OS at 1 year (%) 75% 56% 52% OS at 2 years (%) 43% 20% 20% OS at 3 years (%) 29% 11% 4% S. Oudard et al, 2009, 103, 12:

27 M0 Maintain castration levels of testosterone Clinical trial Observation Further hormonal manipulation ASYMPTOMATIC M1 Maintain castration levels of testosterone SYMPTOMATIC only bone mets DOC Zoledronic acid SYMPTOMATIC visceral mets DOC

28 M0 Maintain castration levels of testosterone Clinical trial Observation Further hormonal manipulation ASYMPTOMATIC T slow growth Clinical trial Further hormonal manipulation Immunotherapy M1 Maintain castration levels of testosterone ASYMPTOMATIC fast growth SYMPTOMATIC only bone mets DOC Clinical trial DOC Zoledronic acid SYMPTOMATIC visceral mets DOC

29 Symptomatic CRPC patients should start CT as soon as possible Asymptomatic CRPC patients with aggressive features should start CT before PS worsening Asymptomatic CRPC patients with no aggressive features should be enrolled in clinical trials or should undergo watchful waiting (no advantages from further HTs)

30

31 New HTs CT Abiraterone Enzalutamide Cabazitaxel Cabazitaxel Doc cetaxel CT New HTs Cabazitaxel Cabazitaxel Abiraterone Enzalutamide New HTs New HTs Abiraterone Enzalutamide Enzalutamide Abiraterone 3 strategies t 6 combinations

32 Abiraterone Enzalutamide Enzalutamide Abiraterone Cabazitaxel Enzalutamide Cabazitaxel Abiraterone Cabazitaxel Cabazitaxel Abiraterone Enzalutamide Abiraterone Cabazitaxel Enzalutamide Cabazitaxel Enzalutamide Abiraterone

33 CT HT vs HT CT

34 CT HT vs HT CT Author sequence # pts brr mos Mezynski ABI DOC 35 26% 12.5 m Aggarwal* KETO DOC % 21.1 m Pond** KETO DOC % 17.0 m *no differences compared to 728 pts not treated with KETO ** better trend without significance compared to 180 pts not treated with KETO after adjustment

35 Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel inmetastatic castration resistant resistant prostate cancer (mcrpc). 113 pts assessed 77 pts 36 pts Caba Abi Abi Caba Median OS, TTF1, and TTF2 were analyzed by Kaplan Meier method from start of second line therapy post D to death for OS, to end of second line (TTF1), and to end of combined second and third line therapies (TTF2). Sonpavde et al. ESMO 2013, abs 2905

36 Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel inmetastatic castration resistant resistant prostate cancer (mcrpc). Sonpavde et al. ESMO 2013, abs 2905

37 Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel inmetastatic castration resistant resistant prostate cancer (mcrpc). Median TTF1 Median TTF2 DCA: 5.2 mos (95% CI 4.3 7) DCA: 10.4 mos (95% CI ) DAC: 4.3 mos (95% CI ) DAC: 7.1 mos (95% CI ) Sonpavde et al. ESMO 2013, abs 2905

38 Sella a et al. ASCO GU 2013 Abs 186

39 Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mcrpc) treated with cabazitaxel: Sequencing mightmatter. matter. Angelergues et al. J Clin Oncol 31, 2013 (suppl; abstr 5063)

40 ENZ ABI vs ABI ENZ

41 ENZ ABI vs ABI ENZ

42 ENZ ABI vs ABI ENZ Author sequence # pts brr mpfs Loriot ENZ ABI 38 8% 2.7 m Noonan ENZ ABI 30 3% 3.8 m Schrader ABI ENZ % NR Bianchini ABI ENZ % 28m 2.8

43 A decision making flow chart proposal Gallardo et al. Crit Rev Oncol/Hemat 2013, in press

44 l id i No clear evidence supports one sequencing strategy vs another Preliminary and observational experiences suggest CABA before HTs seems to provide better survival outcomes HT HT activity seems to be limited To date the sequencing strategy should be tailored to the single patient profile (when it is possible, more lines seem better)

45

46 Sipuleucel T: Autologous APCs Cultured with Antigen Fusion Protein Recombinant Prostatic Acid Phosphatase (PAP) fusion antigen combines with resting antigen presenting cell (APC) APC takes up the antigen Antigen is processed and presented on surface of the APC Active T-cell Fully activated, the APC is now sipuleucel-t Inactive INFUSE PATIENT T-cell T-cells proliferate and attack cancer cells sipuleucel-t activates T-cells in the body The precise mechanism of sipuleucel-t in prostate cancer has not been established.

47 PSA TRICOM (PROSTVAC) is a vector based vaccine consisting of recombinant fowlpox boosts which contains transgenes for PSA and three co stimulatory molecules (TRICOM)

48 Randomized Phase 3 IMPACT Trial (IMmunotherapy Prostate AdenoCarcinoma Treatment) Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate t Cancer (N=512) 2:1 Sipuleucel-T Q 2 weeks x 3 Placebo Q 2 weeks x 3 P R O G R E S S I O N Treated at Physician Discretion Treated at Physician Discretion and/or Salvage Protocol S U R V I V A L Primary Endpoint: Overall Survival Secondary Endpoint: Objective Disease Progression

49 P = (Cox model) HR = [95% CI: 0.614, 0.979] Median Survival Benefit = 4.1 Mos. (25.8 vs 21.7)

50 Metastatic Castration Resistant Prostate Cancer (N=125) 2:1 PROSTVAC Q 4 weeks x 6 Placebo Q 4 weeks x 6 Primary Endpoint: Progression Free Survival

51

52

53 Tumor Growth Rate Tumor Bu urden Time

54 Sipuleucel T: Logistics of Therapy Day 1 Day 2-3 Day 3-4 Leukapheresis sipuleucel-t is manufactured Patient is infused Apheresis Center Central Processing Doctor s Office COMPLETE COURSE OF THERAPY: COMPLETE COURSE OF THERAPY: Weeks 0, 2, 4

55 No clear evidences supports the advantages of an immunotherapy strategy for the largest majority of CRPC pts Economic and factory matters will limit its use in Italian context

56

57 parameters clinical issues performance status pain laboratory issues PSA bone biomarkers imaging issues CT scan bone scan PET scan (??)

58 objectives true PD to avoid late therapy stop (for on treatment pts) to avoid later therapy start (for off treatment pts) false PD to avoid early therapy stop (for on treatment pts) to avoid early therapy start (for off treatment pts)

59 on treatment regular PSA assessment biochemical PD requires radiological confirmation of progression to lead to therapy end regular clinical status assessment baseline and final instrumental assessment CT : on demand during the treatment HT : every 4 6 months

60 off treatment regular PSA assessment biochemical PD should be confirmed by radiological assessment clinical status should be regularly monitored to avoid a deterioration which prevents further treatments to detect symptoms appearance no regular instrumental follow up should be planned

When exogenous testosterone therapy is. adverse responses can be induced.

When exogenous testosterone therapy is. adverse responses can be induced. Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release

More information

Until 2004, CRPC was consistently a rapidly lethal disease.

Until 2004, CRPC was consistently a rapidly lethal disease. Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different

More information

Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy

Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS

More information

2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC

2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;

More information

Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)

Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory

More information

Prostate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone

Prostate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal

More information

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract

More information

Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T

Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater

More information

Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN

Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates

More information

Management of castrate resistant disease: after first line hormone therapy fails

Management of castrate resistant disease: after first line hormone therapy fails Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support

More information

Perspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy

Perspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for

More information

X, Y and Z of Prostate Cancer

X, Y and Z of Prostate Cancer X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios

More information

Cancer de la prostate métastatique: prise en charge précoce

Cancer de la prostate métastatique: prise en charge précoce Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016

More information

What will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents

What will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for

More information

Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success

Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success EORTC-GU Group Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success Joaquim Bellmunt Geriatric Oncology: Cancer in Senior Adults. Madrid Melia Castilla, 8-10 November 2007. Multidisciplinary

More information

Updated Results of the IMPACT. Metastatic, Castration-Resistant Prostate Cancer (CRPC)

Updated Results of the IMPACT. Metastatic, Castration-Resistant Prostate Cancer (CRPC) Updated Results of the IMPACT Trial of Sipuleucel-T Tfor Metastatic, Castration-Resistant Prostate Cancer (CRPC) Philip Kantoff, MD Dana-Farber a abe Cancer Institute ue Professor of Medicine Harvard Medical

More information

Early Chemotherapy for Metastatic Prostate Cancer

Early Chemotherapy for Metastatic Prostate Cancer Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,

More information

Evolution of Chemotherapy for. Cancer

Evolution of Chemotherapy for. Cancer Evolution of Chemotherapy for Hormone Refractory Prostate t Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology Princess Margaret Hospital and University of Toronto In 1985, two

More information

Chemohormonal Therapy For Prostate Cancer. What is old, is new again!

Chemohormonal Therapy For Prostate Cancer. What is old, is new again! Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology

More information

Name of Policy: Cellular Immunotherapy for Prostate Cancer

Name of Policy: Cellular Immunotherapy for Prostate Cancer Name of Policy: Cellular Immunotherapy for Prostate Cancer Policy #: 432 Latest Review Date: July 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits are payable

More information

Incorporating New Agents into the Treatment Paradigm for Prostate Cancer

Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center

More information

SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223

SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:

More information

Advanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options

Advanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and

More information

mcrpc in 2016 How to decide the optimal treatment? N. Mottet

mcrpc in 2016 How to decide the optimal treatment? N. Mottet mcrpc in 2016 How to decide the optimal treatment? N. Mottet Disclosures Conflict of interest Chairman EAU PCa guidelines..... Therefore I'm 100% biased Castrate-resistant prostate cancer (CRPC) Definition

More information

Optimizing Outcomes in Advanced Prostate Cancer

Optimizing Outcomes in Advanced Prostate Cancer Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase

More information

Patients Living Longer: The Promise of Newer Therapies

Patients Living Longer: The Promise of Newer Therapies Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890

More information

Philip Kantoff, MD Dana-Farber Cancer Institute

Philip Kantoff, MD Dana-Farber Cancer Institute CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests

More information

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043. Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate

More information

www.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)

More information

David L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer

David L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer David L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer isbtc 22 nd Annual Meeting, Boston November 4, 2007 1 Forward

More information

ESMO SUMMIT MIDDLE EAST 2018

ESMO SUMMIT MIDDLE EAST 2018 ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche

More information

ASCO 2012 Genitourinary tumors

ASCO 2012 Genitourinary tumors ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase

More information

PROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute

PROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis

More information

Management of castration resistant prostate cancer after first line hormonal therapy fails

Management of castration resistant prostate cancer after first line hormonal therapy fails Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?

More information

Published on The YODA Project (

Published on The YODA Project ( Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34

More information

Advanced Prostate Cancer

Advanced Prostate Cancer Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University

More information

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is

More information

Updates in Prostate Cancer Treatment 2018

Updates in Prostate Cancer Treatment 2018 Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant

More information

Challenging Cases. With Q&A Panel

Challenging Cases. With Q&A Panel Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy

More information

PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog

PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/

More information

Group Sequential Design: Uses and Abuses

Group Sequential Design: Uses and Abuses Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential

More information

Management of Prostate Cancer

Management of Prostate Cancer Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and

More information

Joelle Hamilton, M.D.

Joelle Hamilton, M.D. Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT

More information

Advanced Prostate Cancer. November Jose W. Avitia, M.D

Advanced Prostate Cancer. November Jose W. Avitia, M.D Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000

More information

Management of castrate resistant disease: after first line hormone therapy fails

Management of castrate resistant disease: after first line hormone therapy fails Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The

More information

Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey

Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate

More information

African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study

African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate

More information

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy

More information

mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE

mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL

More information

Novel treatment for castration-resistant prostate cancer

Novel treatment for castration-resistant prostate cancer Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients

More information

GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017

GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017 GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research

More information

Management of mcrpc: Hormonal therapy and treatment sequence for CRPC

Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials

More information

Second line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017

Second line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers

More information

Immunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Immunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,

More information

- La Terapia Farmacologica -

- La Terapia Farmacologica - XXV Congresso Nazionale AIRO Simposio AIRO-AIMN: Trattamento delle Metastasi Ossee nel Paziente con Tumore della Prostata "Ormonorefrattario": - La Terapia Farmacologica - Sergio Bracarda, Medical Oncology

More information

Strategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)

Strategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc) Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc

More information

Immunotherapy of Prostate Cancer

Immunotherapy of Prostate Cancer Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines

More information

Current role of chemotherapy in hormone-naïve patients Elena Castro

Current role of chemotherapy in hormone-naïve patients Elena Castro Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of

More information

PROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer

PROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer PROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer James L. Gulley M.D., Ph.D., F.A.C.P. Director, Clinical Trials

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease

More information

Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering

Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering > Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific

More information

The Role of Immunotherapy in Prostate Cancer: What s Trending?

The Role of Immunotherapy in Prostate Cancer: What s Trending? The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies

More information

Management of castrate resistant disease; after first line hormone therapy fails

Management of castrate resistant disease; after first line hormone therapy fails Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge

More information

David L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer

David L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer David L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer Hot Topic Symposium; isbtc Annual Meeting October 31, 2009 1 Presenter Disclosure Information

More information

Index Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death

Index Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death //4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8

More information

Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?

Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature

More information

Management of Incurable Prostate Cancer in 2014

Management of Incurable Prostate Cancer in 2014 Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis

More information

Advanced Prostate Cancer

Advanced Prostate Cancer Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen

More information

Immunotherapy Therapy for Prostate Cancer

Immunotherapy Therapy for Prostate Cancer 2006 Prostate Health Education Network African American Prostate Cancer Disparity Summit Immunotherapy Therapy for Prostate Cancer Glen W. McWilliams, MD Chief of Urology James J. Peters VAMC Assistant

More information

The Current Prostate Cancer Landscape

The Current Prostate Cancer Landscape A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer

More information

New Treatment Options for Prostate Cancer

New Treatment Options for Prostate Cancer New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer

More information

Secondary Hormonal therapies in mcrpc

Secondary Hormonal therapies in mcrpc Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder

More information

Advanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin

Advanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,

More information

Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy

Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy DOI:10.1093/jnci/djt280 Advance Access publication October 17, 2013 The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

More information

Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi

Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi

More information

The Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist

The Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy

More information

SUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments

SUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival

More information

Oligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?

Oligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for

More information

SEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT

SEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT SEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT Eleni Maragkouli, Medical Oncologist Oncology Department The University of Thessaly, Medical School University Hospital of Larissa, Greece Tumour volume

More information

Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,

More information

*For reprints and all correspondence: Nobuaki Matsubara, Kashiwanoha, Kashiwa, Chiba , Japan.

*For reprints and all correspondence: Nobuaki Matsubara, Kashiwanoha, Kashiwa, Chiba , Japan. Japanese Journal of Clinical Oncology, 2015, 45(8) 774 779 doi: 10.1093/jjco/hyv070 Advance Access Publication Date: 15 May 2015 Original Article Original Article A multicenter retrospective analysis of

More information

Initial Hormone Therapy

Initial Hormone Therapy Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA

More information

Mitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006

Mitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006 Mitchell H. Gold, M.D. President and CEO 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006 1 Dendreon Corporation: A Biotechnology Company on the Verge of Changing the Way

More information

ADT vs chemo + ADT as initial treatment for advanced prostate cancer

ADT vs chemo + ADT as initial treatment for advanced prostate cancer ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread

More information

CME Baseline Curriculum Report

CME Baseline Curriculum Report CME Baseline Curriculum Report October 14, 2010 For CME Activity: Managing Advanced Prostate Cancer in the Community Setting: A Case-based Curriculum Supported by an independent educational grant from

More information

8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases

8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)

More information

INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER

INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:

More information

Prostate cancer Management of metastatic castration sensitive cancer

Prostate cancer Management of metastatic castration sensitive cancer 18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial

More information

Timing of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model

Timing of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information

Maintenance paradigm in non-squamous NSCLC

Maintenance paradigm in non-squamous NSCLC Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons

More information

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

Treatment sequencing in metastatic castrate resistant prostate cancer

Treatment sequencing in metastatic castrate resistant prostate cancer (2014) 16, 426 431 2014 AJA, SIMM & SJTU. All rights reserved 1008 682X www.asiaandro.com; www.ajandrology.com Prostate Cancer Open Access REVIEW Treatment sequencing in metastatic castrate resistant prostate

More information

Hormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK

Hormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component

More information

Castrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Castrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,

More information

In autopsy, 70% of men >80yr have occult prostate ca

In autopsy, 70% of men >80yr have occult prostate ca Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease

More information

Convegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena

Convegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH

More information

Bone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France

Bone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,

More information

sipuleucel-t (Provenge )

sipuleucel-t (Provenge ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information